Metastatic Colorectal Cancer
Expanded cohort to 25613 patients, including 1855 academic patients in the cohort
Advanced Gastric/Esophageal Cancer
Expanded cohort to 10118 patients, including 926 academic patients in the cohort
Chronic Lymphocytic Leukemia
Expanded cohort to 11842 patients, including 832 academic patients in the cohort
Acute Myeloid Leukemia
Expanded cohort to 3897 patients, including 827 academic patients in the cohort
Multiple Myeloma
Expanded cohort to 11096 patients, including 1464 academic patients in the cohort
Metastatic Renal Cell Carcinoma
Expanded cohort to 8685 patients, including 1003 academic patients in the cohort
Advanced Urothelial Carcinoma
Expanded cohort to 8938 patients, including 785 academic patients in the cohort
Ovarian Cancer
Expanded cohort to 7274 patients, including 961 academic patients in the cohort
Follicular Lymphoma
Expanded cohort to 3843 patients, including 493 academic patients in the cohort
Advanced Non-Small Cell Lung Cancer
Expanded cohort to 62908 patients, including 5877 academic patients in the cohort
Small-Cell Lung Cancer
Expanded cohort to 7154 patients, including 475 academic patients in the cohort
Metastatic Pancreatic Cancer
Expanded cohort to 9948 patients, including 1576 academic patients in the cohort
Diffuse Large B-Cell Lymphoma
Expanded cohort to 6771 patients, including 973 academic patients in the cohort
Advanced Head & Neck Cancer
Expanded cohort to 7296 patients, including 692 academic patients in the cohort
Advanced Melanoma
Expanded cohort to 10119 patients, including 1695 academic patients in the cohort
Metastatic Breast Cancer
Expanded cohort to 22870 patients, including 1612 academic patients in the cohort
Early Breast Cancer
Expanded cohort to 9774 patients, including 1073 academic patients in the cohort
Key Highlights
Placeholder text
Lab Updates
Due to additional improvements made to source data mapping, partners can expect to see a 1-2% increase (some variance by dataset) in rows with complete XXX values. These improvements apply to distinct test names and both prior and future lab values will benefit from this change.
As part of ongoing lab maintenance, lab records associated with LOINC XXX will map to LOINC XXX.
The XXX values for granulocyte lab records with LOINCs XXX, XXX, and XXX have been changed from 10*9/mL to 10*9/L. It is no longer necessary to conduct manual unit conversions to compare these results with other lab tests on the Complete Blood Count panel (e.g. neutrophil values).
Network Changes
Patient data associated with Practice ID XXX will not be updated while Flatiron makes necessary adjustments to data integrations (as soon as March or April 2020 deliverable(s)) due to an in-network acquisition. Data from this Practice ID will be newly associated with the parent Practice ID, XXX, once the migration is complete. Analyses reliant on longitudinal information from this Practice ID with a less than 60 day recency may be impacted. Please let your Flatiron contact know if you have questions about how to assess impact.
As part of ongoing data quality and compliance checks with our practices, practice XXX is scheduled to exit the Flatiron OncoEMR® network. As of this delivery, Flatiron has removed all records associated with the site from our research datasets. There are no expected decreases in any dataset sizes and Flatiron will replace patient records as needed to ensure cohort growth.
Knowledge Center
In response to your feedback, we have uploaded information about spotlight projects to Your Subscription page of the Flatiron Knowledge Center. Data dictionaries and analytic guides for each project can now also be found in the Spotlight Project Resources section. We hope this update makes it easier for teams to understand what Spotlight data are available to them, as well as provide the ability to easily access tailored guidance by project.
Comments
0 comments
Please sign in to leave a comment.